Daxor Corporation

254 articles with Daxor Corporation

• Daxor Awarded $1.1 Million Contract from United States Department of Defense (DOD) for Rapid Portable Blood Volume Analyzer

  4/23/2020

  Daxor Corporation, an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, announced that the United States Department of Defense has awarded the Company a $1.1 million contract for the development and deployment of a small, portable, highly accurate, battery-powered Blood Volume Analyzer.

• Daxor Corporation’s BVA-100® Test Used to Guide Treatment In COVID-19 Patient

  3/20/2020

  Daxor Corporation today announced the first use of its BVA-100 test to guide volume treatment in a patient infected with the COVID-19 virus. The company also announced the release of a clinical protocol for fluid guidance when ut

• 

  Biopharma Industry News for March 20: Update on the Novel Coronavirus

  3/20/2020

  A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.

• Daxor Corporation Contracted to Adapt Its Blood Volume Analyzer Technology for U.S. Air Force Needs

  3/9/2020

  Daxor Corporation(NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that the U.S. Air Force (USAF) has awarded Daxor a contract to define specifications to adapt blood volume analysis technology to meet the needs of USAF.

• Daxor Corporation Announces Closing of $2.0 Million Registered Direct Offering Priced At-The-Market

  3/6/2020

  Daxor Corporation(NYSE American: DXR) (“Daxor” or the “Company”), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has closed its previously announced registered direct offering priced at-the-market of 140,352 shares of its common stock at a price of $14.25 per share, for aggregate gross proceeds of approximately $2.0 million.

• Daxor Corporation Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market

  3/3/2020

  Daxor Corporation (NYSE American: DXR) (“Daxor” or the “Company”), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 140,352 shares of its common stock at a price of $14.25 per share, for aggregate gross proceeds of approximately $2.0 million, in a registered direct offering priced at-the-market

• DAXOR CORPORATION ANNOUNCES RISE IN KIT SALES AND FILES FORM N-CSR FOR 2019

  3/2/2020

  Daxor Corporation (NYSE MKT: DXR) disclosing its schedule of portfolio holdings as of December 31, 2019.

• Daxor Corporation Announces Engagement with Hospitals and Government for Use of the Blood Volume Analyzer (BVA-100®) to Stem COVID-19 Deaths

  3/2/2020

  Daxor Corporation(NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces active engagement with both hospitals and government agencies in the military and civilian sectors regarding the use of its technology to help guide fluid management of critically ill patients with COVID-19.

• New Research Further Demonstrates Clinical Superiority of Daxor Corporation’s Blood Volume Analyzer (BVA-100®) in Critical Care

  2/20/2020

  NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new research from the University of Hawaii John A. Burns School of Medicine further demonstrates the clinical superiority of accurate and direct quantification of intravascular blood volume in critically ill patients compared with ultrasound measurement. The new study was

• Daxor Corporation to Exhibit at the Society for Critical Care Medicine 49th Congress

  2/12/2020

  Daxor Corporation(NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the Society for Critical Care Medicine (SCCM) 49th Congress at the Orlando Convention Center in Orlando, FL, from February 16-18th, 2019.

• Novel Study from Yale University Utilizes Daxor’s Blood Volume Analyzer (BVA-100®) to Uncover Important Mechanism for Drug Empagliflozin

  11/21/2019

  Daxor Corporation(NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces new data from The Yale University School of Medicine that was presented on November 16th at the American Heart Association Scientific Sessions in Philadelphia, PA.

• Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2019

  11/12/2019

  Daxor Corporation(NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the American Heart Association Scientific Sessions (AHA) at the Philadelphia Convention Center in Philadelphia, PA from November 16-18th, 2019.

• Daxor to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 1:30 PM Central Time

  10/10/2019

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, announced that Michael Feldschuh, Chief Executive Officer of Daxor, will be a featured presenter at the inaugural MicroCap Rodeo Investor Conference in Austin, Texas at the Hilton Austin on Tuesday, October 15th at 1:30 PM (CT).

• Newly Published Data Show Daxor Corporation’s BVA-100 Is Superior To Formula-Based Estimates of Blood Volume In Assessing Patients With Heart Failure

  8/20/2018

  Daxor Corporation today announces the publication of an investigator-initiated study from Duke University and The Mayo Clinic demonstrating that despite the widespread use of formula-derived estimates of plasma volume in heart failure patients.

• Daxor Corporation Appoints Kathryn A. Kornafel Vice President of Marketing and Commercial Development

  6/12/2018

  Daxor Corporation announces the appointment of Kathryn A. Kornafel as vice president of Marketing and Commercial Development.

• Daxor Corporation Revises 2017 Dividend

  12/29/2017

  This dividend will be paid on Friday, January 12, 2018 to Daxor shareholders of record on Monday January 8, 2018.

• Daxor Corporation Announces 2017 Dividend

  12/21/2017

  Daxor Corporation announced the payment of a dividend for 2017.

• Daxor Corporation Announces Share Buyback Program

  11/1/2017

  The Board of Directors of Daxor has voted to re-authorize the company’s share buyback for an amount of up to 300,000 shares for the next 12 months.

• Daxor Corporation Forwarding Plans To Expand Impact At HFSA 2017 And Beyond

  9/19/2017

• Daxor Corporation Holds Annual Meeting, Provides Business Growth Update And Strategic Plan

  6/30/2017